- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 107
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 31 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- Certolizumab Pegol, Etanercept, Placebo
- Biological · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Months to 29 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
- Conditions
- Hepatitis C Virus
- Interventions
- Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- PEG-rIL-29, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- ZymoGenetics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Coronado, California • La Jolla, California + 26 more
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
- Interventions
- PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Miami, Florida + 12 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
- Conditions
- T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone, doxorubicin hydrochloride, thioguanine, radiation therapy, nelarabine, pegaspargase, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- HIV Infections
- Interventions
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Drug
- Lead sponsor
- The Wistar Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 120 more
- Conditions
- Melanoma (Skin)
- Interventions
- PEG-interferon alfa-2b
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Lakeland, Florida • Bloomington, Illinois + 22 more
- Conditions
- Chronic Hepatitis b
- Interventions
- AB-729, Peg-IFNα-2a
- Drug
- Lead sponsor
- Arbutus Biopharma Corporation
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Chandler, Arizona • Tucson, Arizona • San Diego, California + 3 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Certolizumab pegol
- Other · Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab pegol (CDP870)
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 19
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 1,895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 191
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more